The review (Universidad AutΓ³noma de Madrid) organizes SPE-based ECL biosensing into three application pillars β immunosensors, enzymatic biosensors, and DNA sensors β after an introductory treatment of annihilation vs. co-reactant ECL mechanisms, luminol, [Ru(bpy)3]2+/TPrA, and S2O82β chemistry . This mechanistic framing is its strongest pedagogical value for newcomers.
Units differ across studies (fg/mL vs CFU/mL vs mU/mL), so bars are only indicative of relative reported sensitivity β cross-study comparison is inherently limited, a limitation the review itself does not address with standardized benchmarks.
Reported detection limits span ~7 orders of magnitude: from 1 fg/mL for Ξ²2-microglobulin and thyroglobulin to 0.4 mU/mL for CA125, with multiplex pathogen DNA detection at 0.6β1.2 nmol/L . The nanomaterial section (CdTe QDs, g-C3N4, SnO2@PtRu, graphene, CNTs) is thorough and current as of 2020. However, most cited works validated performance only in buffer or mildly diluted serum with small replicates (n=3), not in blinded clinical cohorts β a translational gap common to the field that the review acknowledges but does not systematically quantify.
The text shows notable internal duplication (several paragraphs repeated verbatim), likely editorial/GROBID extraction artifacts, which weakens readability. LOD values are not normalized by matrix, incubation time, or electrode chemistry, so the impressive fg/mL figures cannot be directly benchmarked against commercial Roche ECL analyzers despite one study reporting agreement (RSD 2.84β7.31%). The review is non-systematic (no PRISMA protocol), risking positive-result and citation bias. Confidence in its descriptive accuracy: high; confidence in implied POC readiness: low-moderate β real-world stability, regeneration, and multi-lab reproducibility remain open questions.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.